224 related articles for article (PubMed ID: 23878723)
21. Architecture and membrane interactions of the EGF receptor.
Arkhipov A; Shan Y; Das R; Endres NF; Eastwood MP; Wemmer DE; Kuriyan J; Shaw DE
Cell; 2013 Jan; 152(3):557-69. PubMed ID: 23374350
[TBL] [Abstract][Full Text] [Related]
22. Disabling receptor ensembles with rationally designed interface peptidomimetics.
Berezov A; Chen J; Liu Q; Zhang HT; Greene MI; Murali R
J Biol Chem; 2002 Aug; 277(31):28330-9. PubMed ID: 12011054
[TBL] [Abstract][Full Text] [Related]
23. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.
Murali R; Brennan PJ; Kieber-Emmons T; Greene MI
Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6252-7. PubMed ID: 8692801
[TBL] [Abstract][Full Text] [Related]
24. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
25. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
[TBL] [Abstract][Full Text] [Related]
26. Evolutionary analysis of the ErbB receptor and ligand families.
Stein RA; Staros JV
J Mol Evol; 2000 May; 50(5):397-412. PubMed ID: 10824084
[TBL] [Abstract][Full Text] [Related]
27. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms.
Johannessen LE; Haugen KE; østvold AC; Stang E; Madshus IH
Biochem J; 2001 May; 356(Pt 1):87-96. PubMed ID: 11336639
[TBL] [Abstract][Full Text] [Related]
28. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging.
Macdonald-Obermann JL; Piwnica-Worms D; Pike LJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):137-42. PubMed ID: 22190492
[TBL] [Abstract][Full Text] [Related]
29. Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation.
Trenker R; Diwanji D; Bingham T; Verba KA; Jura N
Elife; 2024 Mar; 12():. PubMed ID: 38498590
[TBL] [Abstract][Full Text] [Related]
30. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
Jin P; Zhang J; Beryt M; Turin L; Brdlik C; Feng Y; Bai X; Liu J; Jorgensen B; Shepard HM
Mol Med; 2009; 15(1-2):11-20. PubMed ID: 19048033
[TBL] [Abstract][Full Text] [Related]
31. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
32. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
33. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Aertgeerts K; Skene R; Yano J; Sang BC; Zou H; Snell G; Jennings A; Iwamoto K; Habuka N; Hirokawa A; Ishikawa T; Tanaka T; Miki H; Ohta Y; Sogabe S
J Biol Chem; 2011 May; 286(21):18756-65. PubMed ID: 21454582
[TBL] [Abstract][Full Text] [Related]
34. Regulation of the catalytic activity of the EGF receptor.
Endres NF; Engel K; Das R; Kovacs E; Kuriyan J
Curr Opin Struct Biol; 2011 Dec; 21(6):777-84. PubMed ID: 21868214
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
36. Molecular determinants of epidermal growth factor binding: a molecular dynamics study.
Sanders JM; Wampole ME; Thakur ML; Wickstrom E
PLoS One; 2013; 8(1):e54136. PubMed ID: 23382875
[TBL] [Abstract][Full Text] [Related]
37. Syndecan-1 and Syndecan-4 Capture Epidermal Growth Factor Receptor Family Members and the α3β1 Integrin Via Binding Sites in Their Ectodomains: NOVEL SYNSTATINS PREVENT KINASE CAPTURE AND INHIBIT α6β4-INTEGRIN-DEPENDENT EPITHELIAL CELL MOTILITY.
Wang H; Jin H; Rapraeger AC
J Biol Chem; 2015 Oct; 290(43):26103-13. PubMed ID: 26350464
[TBL] [Abstract][Full Text] [Related]
38. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L; Strommen K; Dao-Pick T; Parry G; Goodman L; Winslow J
Breast Cancer Res; 2011 Apr; 13(2):R44. PubMed ID: 21496232
[TBL] [Abstract][Full Text] [Related]
39. HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms.
Hendriks BS; Wiley HS; Lauffenburger D
Biophys J; 2003 Oct; 85(4):2732-45. PubMed ID: 14507736
[TBL] [Abstract][Full Text] [Related]
40. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
Arteaga CL; Ramsey TT; Shawver LK; Guyer CA
J Biol Chem; 1997 Sep; 272(37):23247-54. PubMed ID: 9287333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
